Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antiviral Agents Clear all
Not listed Phase 3 Interventional

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

NCT00009061
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
37
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

NCT03739866
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Lenacapavir, Placebo, B/F/TAF, TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes

NCT00001012
View directory record Official record
Conditions
HIV Infections
Interventions
AL 721
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Los Angeles, California • New Orleans, Louisiana • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

NCT03475212
View directory record Official record
Conditions
Cytomegalovirus Infections, Adenovirus Infection, EBV Infection
Interventions
Virus Specific T-cell (VST) infusion
Biological
Lead sponsor
Pediatric Transplantation & Cellular Therapy Consortium
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

A Study of T-20 in HIV-Positive Adults

NCT00002228
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Trimeris
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 2:10 PM EDT
Active, not recruiting Phase 4 Interventional

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

NCT03520660
View directory record Official record
Conditions
Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
Interventions
Epclusa
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 120 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

NCT00013897
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Lamivudine/Zidovudine, Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

TD-6450 MAD Study in HCV Infected Subjects

NCT02116543
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
TD-6450, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir Phosphate, ADS-8902
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Jun 10, 2026, 2:10 PM EDT
Terminated Phase 4 Interventional Results available

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

NCT03208127
View directory record Official record
Conditions
End Stage Liver Disease, Hepatitis C
Interventions
Treatment with Direct Acting Antiviral tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

NCT03491553
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

NCT00002358
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Sorivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

NCT00623649
View directory record Official record
Conditions
HCV Infection
Interventions
VCH 916, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Jun 10, 2026, 2:10 PM EDT
Terminated No phase listed Observational

Clinical Performance Evaluation of DxN HBV Assay

NCT03123159
View directory record Official record
Conditions
Hepatitis B
Interventions
DxN HBV Assay
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Timeline
2014 – 2017
U.S. locations
8
States / cities
La Jolla, California • Minneapolis, Minnesota • Jackson, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

NCT01950325
View directory record Official record
Conditions
HIV-1 Infection, Neutralizing Antibody, Monoclonal Antibody, Viral Load, HIV Antibodies
Interventions
VRC-HIVMAB060-00-AB
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

NCT00774397
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 201335 NA 240 mg QD / LI, PegIFN/RBV, BI 201335 NA 120mg QD / LI, BI 201335 NA 240 mg QD, BI 201335 NA 240 mg BID, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
San Francisco, California • Chicago, Illinois • Lutherville, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2015 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients

NCT00101374
View directory record Official record
Conditions
HIV Infections
Interventions
Leflunomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Not applicable Interventional

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

NCT00002155
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Results available

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

NCT02609399
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Peramivir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients

NCT00001116
View directory record Official record
Conditions
HIV Infections
Interventions
Tumor Necrosis Factor soluble receptor-immunoadhesin complex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
Honolulu, Hawaii • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

NCT00002116
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Cidofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Not applicable Interventional

A Study of Lobucavir in Patients With AIDS

NCT00002352
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Lobucavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

NCT06214052
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Matching Placebo, Antiretroviral therapy
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Bakersfield, California • Los Angeles, California • West Hollywood, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jun 10, 2026, 2:10 PM EDT